KR830008684A - 면역 글로불린 접합체의 제조방법 - Google Patents

면역 글로불린 접합체의 제조방법

Info

Publication number
KR830008684A
KR830008684A KR1019820000104A KR820000104A KR830008684A KR 830008684 A KR830008684 A KR 830008684A KR 1019820000104 A KR1019820000104 A KR 1019820000104A KR 820000104 A KR820000104 A KR 820000104A KR 830008684 A KR830008684 A KR 830008684A
Authority
KR
South Korea
Prior art keywords
immunoglobulin
immunoglobulin conjugate
preparing immunoglobulin
conjugate
fragment
Prior art date
Application number
KR1019820000104A
Other languages
English (en)
Other versions
KR860001149B1 (ko
Inventor
훼르디난드 로울란드 조오지
조오지 시몬스 로빈
Original Assignee
테렌스 로저 크로우더
릴리 인더스트리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테렌스 로저 크로우더, 릴리 인더스트리스 리미티드 filed Critical 테렌스 로저 크로우더
Publication of KR830008684A publication Critical patent/KR830008684A/ko
Application granted granted Critical
Publication of KR860001149B1 publication Critical patent/KR860001149B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

면역 글로불린 접합체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 면역 글로불린 또는 면역 글로불린 단편을 데스아세틸빈블라스틴산 아지드와 반응시켜서 제조한 공유 결합하고있는 다음 일반식(II)의 하나 또는 그이상의 기로 개량시켜서 제조함을 특징으로하는 면역 글로블린 또는 면역 글로불린 단편으로된 접합체의 제조방법.
  2. 청구범위 1에 있어서, 접합체가 IgG면역 글로불린임을 특징으로하는 접합체의 제조방법.
  3. 청구범위 1이나 2에 있어서, 면역 글로불린 또는 면역 글로불린 단편이 2-5의 일반식 (II)의 기에 의하여 개량됨을 특징으로 하는 방법.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR8200104A 1981-01-12 1982-01-12 면역 글로불린 접합체의 제조방법 KR860001149B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8100847 1981-01-12
GB8100847 1981-01-12
FR8100847 1981-01-15

Publications (2)

Publication Number Publication Date
KR830008684A true KR830008684A (ko) 1983-12-12
KR860001149B1 KR860001149B1 (ko) 1986-08-18

Family

ID=10518931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8200104A KR860001149B1 (ko) 1981-01-12 1982-01-12 면역 글로불린 접합체의 제조방법

Country Status (27)

Country Link
EP (1) EP0056322B1 (ko)
JP (1) JPS57136529A (ko)
KR (1) KR860001149B1 (ko)
AT (1) ATE16603T1 (ko)
AU (1) AU549495B2 (ko)
BG (1) BG40318A3 (ko)
CA (1) CA1180660A (ko)
CS (1) CS235525B2 (ko)
DD (1) DD201447A5 (ko)
DE (1) DE3267474D1 (ko)
DK (1) DK5982A (ko)
EG (1) EG15599A (ko)
ES (1) ES508633A0 (ko)
FI (1) FI820020L (ko)
GB (1) GB2090837B (ko)
GR (1) GR75182B (ko)
HU (1) HU186025B (ko)
IE (1) IE52239B1 (ko)
IL (1) IL64722A (ko)
MX (1) MX7215E (ko)
NZ (1) NZ199421A (ko)
PH (1) PH18031A (ko)
PL (1) PL128529B1 (ko)
PT (1) PT74252B (ko)
RO (1) RO82758B (ko)
SU (1) SU1069628A3 (ko)
ZA (1) ZA82122B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
ATE57187T1 (de) * 1983-03-30 1990-10-15 Lilly Industries Ltd Vincaleukoblastin-derivate.
GR79899B (ko) * 1983-03-30 1984-10-31 Lilly Industries Ltd
HUT34212A (en) * 1983-04-29 1985-02-28 Omnichem Sa Process for the production of new vindblastin conjugates
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
US4667030A (en) * 1985-06-17 1987-05-19 Eli Lilly And Company Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids
FI860456A (fi) * 1985-07-16 1987-01-17 Huhtamaeki Oy Laeaeketehdas Le Bis-indolalkaloiders proteinkonjugat, bis-indolalkaloider, deras framstaellning och anvaendning.
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5043340A (en) * 1990-04-03 1991-08-27 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxhydrazide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions
FR2349335A1 (fr) * 1976-04-28 1977-11-25 Inst Int Pathologie Cellulaire Complexes d'alcaloides bis-indoliques du type vinblastine avec la tubuline, leur procede d'obtention et leur utilisation
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation

Also Published As

Publication number Publication date
EP0056322B1 (en) 1985-11-21
GB2090837B (en) 1984-07-18
IL64722A (en) 1985-07-31
SU1069628A3 (ru) 1984-01-23
IE820023L (en) 1982-07-12
PT74252A (en) 1982-02-01
FI820020L (fi) 1982-07-13
DK5982A (da) 1982-07-13
CS235525B2 (en) 1985-05-15
RO82758B (ro) 1984-01-30
ZA82122B (en) 1983-07-27
IE52239B1 (en) 1987-08-19
CA1180660A (en) 1985-01-08
ES8304149A1 (es) 1983-02-16
PL128529B1 (en) 1984-02-29
IL64722A0 (en) 1982-03-31
GR75182B (ko) 1984-07-13
PL234695A1 (ko) 1982-07-19
DE3267474D1 (en) 1986-01-02
MX7215E (es) 1988-01-08
RO82758A (ro) 1984-01-14
BG40318A3 (en) 1986-11-14
AU7927482A (en) 1982-07-22
ES508633A0 (es) 1983-02-16
NZ199421A (en) 1984-08-24
AU549495B2 (en) 1986-01-30
GB2090837A (en) 1982-07-21
PT74252B (en) 1983-08-24
ATE16603T1 (de) 1985-12-15
HU186025B (en) 1985-05-28
EG15599A (en) 1986-06-30
JPS57136529A (en) 1982-08-23
PH18031A (en) 1985-03-06
EP0056322A1 (en) 1982-07-21
DD201447A5 (de) 1983-07-20
KR860001149B1 (ko) 1986-08-18

Similar Documents

Publication Publication Date Title
KR830008684A (ko) 면역 글로불린 접합체의 제조방법
KR850003414A (ko) (2-니트록시메틸-6-클로로피리딘)과 (β-사이클로덱스트린)의 교합화합물의 제조방법
KR830009084A (ko) 퀴놀린 카복실산 유도체의 제조방법
KR840005101A (ko) 2-퀴놀린유도체의 제조방법
KR830006198A (ko) 시클로헥산 유도체의 제조방법
KR830005863A (ko) 인체 융모성선자격 호르몬의 제조방법
KR860001083A (ko) 신규의 모르포리놀의 제법
KR830005191A (ko) 푸란유도체의 제조방법
KR830001890A (ko) 카바졸 유도체의 제조방법
KR850008658A (ko) 베반톨올의 제법
KR830010091A (ko) 구연산 나프티드로푸릴의 제조방법
KR880000411A (ko) 벤조구아나민 유도체의 제법
KR850001737A (ko) N,n-디메틸-2-클로로-5-[3-메틸-2-(페닐이미노)-4-티아졸린-4-일]-페닐설폰아미이드의 포합화합물의 제조방법
KR830009044A (ko) 3,5-디-3급부틸-4-하이드록시페닐-치환 복소환 화합물의 제조방법
KR840000503A (ko) 4-벤조일-5-히드록시 피라졸계 화합물의 제조방법
KR830001203A (ko) N-(1-메틸-2-필로리디닐-메틸)-2,3-디메톡시-5-메틸설파모일 벤즈아미드의 제조방법
KR840002367A (ko) 3-메틸-3-(4-아세틸아미노펜옥시)-2,4-디옥사벤조-사이클로헥사논-1-의 제조방법
KR860004021A (ko) 에틸렌이민 유도체의 제조방법
KR830006215A (ko) 4-저급알킬-3-페녹시피리딘-1-옥사이드의 제조방법
KR830009129A (ko) 유기인산 아미드의 제조방법
KR830006161A (ko) 알킬리덴 디에스테르의 제조방법
KR910000733A (ko) 피롤리진 유도체 제조방법
KR830009130A (ko) 인산 아닐리드 유도체의 제조방법
KR850008487A (ko) 에틸아민 유도체의 제조방법
KR850003395A (ko) 1,4-디하이드로피리딘 유도체의 제조방법